Language

English

Publication Date

12-1-2025

Journal

Journal of Leukocyte Biology

DOI

10.1093/jleuko/qiaf160

PMID

41206685

PMCID

PMC12683237

PubMedCentral® Posted Date

11-7-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Regulatory T cells (Tregs) play a crucial role in the immune system, and their dysfunction can lead to the development of autoimmune conditions. In cancer, tumors frequently hijack the immunosuppressive function of Tregs to evade immune responses. Due to their central role in key pathological processes, Tregs have gained increasing attention as promising targets for various clinical applications. However, their relative scarcity (∼5% to 10% of CD4+ T cells) and instability presents a technical challenge for research and therapeutic development. In congenic animal models used to investigate autologous cell transfer-based therapies, this challenge is even greater, as Treg donor animals may only be able to provide cells to a small number of recipient mice. Here, we present an optimized protocol for ex vivo editing and expansion of mouse Tregs. Because a recent study demonstrated the anticancer potential of SRC-3 KO mouse Tregs, we use them here as a case study.

Keywords

Animals, T-Lymphocytes, Regulatory, Mice, Mice, Knockout, Gene Editing, Mice, Inbred C57BL, cell therapy, CRISPR-Cas9, gene editing, SRC-3, Tregs

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.